Overcoming Resistance to Targeted Therapies in Cancer
| Autor: | Sandra Van Schaeybroeck, Mark Lawler, Anastasia Papafili, Keara Redmond |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Proto-Oncogene Proteins B-raf
Lung Neoplasms Colorectal cancer Receptor ErbB-2 medicine.medical_treatment Fusion Proteins bcr-abl Antineoplastic Agents Breast cancer Leukemia Myelogenous Chronic BCR-ABL Positive medicine Tumor Microenvironment Humans Anaplastic Lymphoma Kinase Molecular Targeted Therapy Lung cancer Melanoma Protein Kinase Inhibitors business.industry Myeloid leukemia Cancer Receptor Protein-Tyrosine Kinases Hematology Immunotherapy Precision medicine medicine.disease ErbB Receptors Oncology Drug Resistance Neoplasm Cancer research business Colorectal Neoplasms |
| Zdroj: | Seminars in oncology. 42(6) |
| ISSN: | 1532-8708 |
| Popis: | The recent discovery of oncogenic drivers and subsequent development of novel targeted strategies has significantly added to the therapeutic armamentarium of anti-cancer therapies. Targeting BCR-ABL in chronic myeloid leukemia (CML) or HER2 in breast cancer has led to practice-changing clinical benefits, while promising therapeutic responses have been achieved by precision medicine approaches in EGFR mutant lung cancer, colorectal cancer and BRAF mutant melanoma. However, although initial therapeutic responses to targeted therapies can be substantial, many patients will develop disease progression within 6-12 months. An increasing application of powerful omics-based approaches and improving preclinical models have enabled the rapid identification of secondary resistance mechanisms. Herein, we discuss how this knowledge has translated into rational, novel treatment strategies for relapsed patients in genomically selected cancer populations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|